Satveer K. Mahil

Feb 19, 2024 | kcl.ac.uk | Satveer K. Mahil

Academic researchers from King’s College London have investigated the early effects of an immunosuppressant drug, which could help clinicians with future personalised approaches for the treatment of psoriasis. The paper, Single-cell analysis of psoriasis resolution demonstrates an inflammatory fibroblast state targeted by IL-23 blockade, is published in Nature Communications online. Psoriasis is a chronic skin disease that affects between one and two million people in the UK.

Feb 14, 2023 | ard.bmj.com | Pedro Machado |Martin Schäfer |Satveer K. Mahil |Jean W. Liew

DiscussionIn this registry-based study of individuals with PsO, PsA and axSpA with SARS-CoV-2 infection, we found that known risk factors for the general population (older age, the presence of comorbidities) and for IMIDs overall (higher disease activity, higher baseline GC usage) were associated with more severe COVID-19 outcomes. In addition, a diagnosis of COVID-19 in a later time period during the pandemic was associated with lower disease severity compared with early 2020.